RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the business operations where the body's immune system is used to fight and eliminate cancer cells. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Rutger Arnhult | 20,41 | 20,41 | 2022-03-31 |
| Anders Ljungqvist | 6,97 | 6,97 | 2022-03-31 |
| Avanza Pension | 5,39 | 5,39 | 2022-03-31 |
| Göran Källebo | 3,34 | 3,34 | 2022-03-31 |
| Nordnet Pensionsförsäkring | 2,62 | 2,62 | 2022-03-31 |
| Gunvald Berger | 1,96 | 1,96 | 2022-03-31 |
| Anders Bremer | 1,31 | 1,31 | 2022-03-31 |
| Nils Berntsson | 1,18 | 1,18 | 2022-03-31 |
| Lennart Sten | 1,16 | 1,16 | 2022-03-31 |
| Ola Forsman | 0,89 | 0,89 | 2022-03-31 |
2022-08-26 Delårsrapport 2022-Q2
2022-11-11 Delårsrapport 2022-Q3
2023-02-10 Bokslutskommuniké 2022